ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory

Grant

Date/time Interval

  • February 26, 2018

    • Awarded By

    Total Award Amount

  • 0.00

    • Direct Costs

  • 0.00

    • Sponsor Award Id